Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

Leukemia
A S MooreS Linardopoulos

Abstract

Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the treatment of FLT3-ITD(+) acute myeloid leukaemia (AML). The paucity of valid pre-clinical models has restricted investigations to determine the mechanism of acquired therapeutic resistance, thereby limiting the development of effective treatments. We generated selective FLT3 inhibitor-resistant cells by treating the FLT3-ITD(+) human AML cell line MOLM-13 in vitro with the FLT3-selective inhibitor MLN518, and validated the resistant phenotype in vivo and in vitro. The resistant cells, MOLM-13-RES, harboured a new D835Y tyrosine kinase domain (TKD) mutation on the FLT3-ITD(+) allele. Acquired TKD mutations, including D835Y, have recently been identified in FLT3-ITD(+) patients relapsing after treatment with the novel FLT3 inhibitor, AC220. Consistent with this clinical pattern of resistance, MOLM-13-RES cells displayed high relative resistance to AC220 and Sorafenib. Furthermore, treatment of MOLM-13-RES cells with AC220 lead to loss of the FLT3 wild-type allele and the duplication of the FLT3-ITD-D835Y allele. Our FLT3-Aurora kinase inhibitor, CCT137690, successfully inhibited growth of FLT3-ITD-D835Y cells in vitro and in vivo, suggesting t...Continue Reading

References

Jan 17, 2003·Leukemia·H QuentmeierH G Drexler
Nov 20, 2003·Nature Reviews. Molecular Cell Biology·Mar Carmena, William C Earnshaw
Nov 25, 2003·Leukemia Research·Maria J CarnicerJorge Sierra
Jun 14, 2006·The Journal of Cell Biology·Gerben VaderSusanne M A Lens
Aug 17, 2006·Journal of Cell Science·Fiona GirdlerStephen S Taylor
Aug 17, 2006·Blood·Soheil MeshinchiJerald P Radich
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hitoshi KiyoiTomoki Naoe
Oct 16, 2007·Bioorganic & Medicinal Chemistry Letters·Vassilios BavetsiasEdward McDonald
Dec 14, 2007·Expert Opinion on Therapeutic Targets·Patrizia Carpinelli, Jürgen Moll
Dec 20, 2007·Molecular Cancer Therapeutics·Florence ChanSpiros Linardopoulos
Jun 25, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Soheil Meshinchi, Frederick R Appelbaum
May 27, 2010·British Journal of Cancer·P WorkmanUNKNOWN Committee of the National Cancer Research Institute
Oct 27, 2010·Human Cell·Hans G Drexler, Roderick A F Macleod
Nov 17, 2010·Blood Reviews·Matthew L SmithDavid Grimwade
Dec 7, 2010·Best Practice & Research. Clinical Haematology·Mark J Levis
Sep 8, 2011·Expert Opinion on Investigational Drugs·Steven Knapper

❮ Previous
Next ❯

Citations

Sep 4, 2012·Immunologic Research·Francesca Alvarez-CalderonJames DeGregori
Apr 9, 2013·Leukemia·A S MooreC M Zwaan
Dec 12, 2012·Journal of Hematology & Oncology·Yao GuoZhizhuang Joe Zhao
Dec 18, 2013·Current Opinion in Hematology·Amer M ZeidanRami S Komrokji
Mar 26, 2014·Current Opinion in Oncology·Laurent Plawny, Fernand Ries
Aug 12, 2014·European Journal of Medicinal Chemistry·Jee Sun YangGyoonhee Han
Nov 21, 2013·Proceedings of the National Academy of Sciences of the United States of America·Emily BaileyDon Small
Oct 15, 2014·Seminars in Hematology·John S Welch
Feb 5, 2013·Expert Opinion on Drug Discovery·Lucas Moreno, Andrew D J Pearson
Jan 7, 2016·Frontiers in Oncology·Vassilios Bavetsias, Spiros Linardopoulos
Mar 5, 2016·Journal of Cancer Research and Clinical Oncology·Jonas Cicenas
Dec 21, 2012·Pediatric Blood & Cancer·Alan S GamisUNKNOWN COG Acute Myeloid Leukemia Committee
Jan 31, 2014·Journal of Experimental & Clinical Cancer Research : CR·Xiaoyu WuXuequan Yao
Apr 22, 2015·British Journal of Haematology·Brunangelo FaliniMaria Paola Martelli
Aug 5, 2014·European Journal of Medicinal Chemistry·Ajit Dhananjay JagtapJi-Wang Chern
Sep 19, 2014·Expert Opinion on Therapeutic Targets·Heiko Konig, Mark Levis
Dec 3, 2014·Clinical Lymphoma, Myeloma & Leukemia·Tapan M KadiaHagop M Kantarjian
Aug 18, 2012·Blood·Ashley F WardKevin M Shannon
Dec 22, 2016·European Journal of Haematology·Amir T Fathi, Yi-Bin Chen
Jun 3, 2014·Therapeutic Advances in Hematology·Seth A WanderAmir T Fathi
Apr 19, 2019·Leukemia & Lymphoma·Kiran Naqvi, Farhad Ravandi
Jan 29, 2014·Current Opinion in Hematology·Keith W Pratz, Selina M Luger
Jul 17, 2012·The Journal of Clinical Investigation·Hanna S RadomskaDaniel G Tenen
Dec 14, 2018·International Journal of Molecular Sciences·Iris Z UrasVeronika Sexl
Apr 15, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ítalo Antônio FernandesElaine Fontes Ferreira da Cunha
Jul 1, 2017·Targeted Oncology·Maximilian StahlAmer M Zeidan

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Assay
electrophoresis
xenograft
flow cytometry
xenografts
transfection

Software Mentioned

GeneMapper
GraphPad Prism

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.